Standout Papers

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer 2019 2026 2021 2023 845
  1. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer (2019)
    Kim N., Neeraj Agarwal et al. New England Journal of Medicine

Immediate Impact

56 standout
Sub-graph 1 of 22

Citing Papers

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
2024 Standout
Alternative splicing and related RNA binding proteins in human health and disease
2024 Standout
2 intermediate papers

Works of Sharon McCarthy being referenced

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
2021
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
2019 Standout

Author Peers

Author Last Decade Papers Cites
Sharon McCarthy 914 325 206 309 27 1.0k
Álvaro Juárez Soto 990 358 210 323 42 1.1k
Vahid Naini 1028 401 231 337 20 1.1k
Per Rathenborg 892 300 299 317 18 1.1k
Murilo Luz 897 290 188 300 30 991
Andrea Juliana Gomes 1289 471 320 421 24 1.4k
Kris Deprince 898 318 228 292 14 1.1k
Iris Kuss 1056 375 240 369 39 1.2k
Youyi Shu 791 251 168 276 13 991
S. Polyakov 774 263 172 263 18 894
Eren Demirhan 657 211 282 224 15 924

All Works

Loading papers...

Rankless by CCL
2026